The stock of Entero Therapeutics Inc. (ENTO) has seen a -45.55% decrease in the past week, with a -63.70% drop in the past month, and a -75.98% decrease in the past quarter. The volatility ratio for the week is 20.23%, and the volatility levels for the past 30 days are at 15.13% for ENTO. The simple moving average for the past 20 days is -51.59% for ENTO’s stock, with a -78.94% simple moving average for the past 200 days.
Is It Worth Investing in Entero Therapeutics Inc. (NASDAQ: ENTO) Right Now?
ENTO has 36-month beta value of 1.35. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENTO is 2.39M, and currently, short sellers hold a 0.38% ratio of that float. The average trading volume of ENTO on July 03, 2024 was 60.51K shares.
ENTO) stock’s latest price update
The stock price of Entero Therapeutics Inc. (NASDAQ: ENTO) has dropped by -12.49 compared to previous close of 1.12. Despite this, the company has seen a fall of -45.55% in its stock price over the last five trading days. globenewswire.com reported 2024-06-27 that New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy
ENTO Trading at -60.51% from the 50-Day Moving Average
After a stumble in the market that brought ENTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.03% of loss for the given period.
Volatility was left at 15.13%, however, over the last 30 days, the volatility rate increased by 20.23%, as shares sank -64.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.30% lower at present.
During the last 5 trading sessions, ENTO fell by -45.55%, which changed the moving average for the period of 200-days by -90.35% in comparison to the 20-day moving average, which settled at $1.9345. In addition, Entero Therapeutics Inc. saw -76.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTO starting from SAPIRSTEIN JAMES, who sale 174 shares at the price of $4.23 back on Apr 01 ’24. After this action, SAPIRSTEIN JAMES now owns 37,105 shares of Entero Therapeutics Inc., valued at $736 using the latest closing price.
Romano Sarah, the Chief Financial Officer of Entero Therapeutics Inc., sale 75 shares at $4.23 during a trade that took place back on Apr 01 ’24, which means that Romano Sarah is holding 19,111 shares at $317 based on the most recent closing price.
Stock Fundamentals for ENTO
Equity return is now at value -15.28, with -12.74 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.
Conclusion
To put it simply, Entero Therapeutics Inc. (ENTO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
